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ABSTRACT 
Post-translational modifications of Proliferating Cell Nuclear Antigen (PCNA) play a 
key role in regulating the bypass of DNA lesions during DNA replication. PCNA can 
be monoubiquitylated at lysine 164 by the RAD6-RAD18 ubiquitin ligase complex. 
Through this modification, PCNA can interact with low fidelity Y family DNA 
polymerases to promote translesion synthesis. Monoubiquitylated PCNA can be 
polyubiquitylated on lysine 63 of ubiquitin by a further ubiquitin-conjugating 
complex. This modification promotes a template switching bypass process in yeast, 
while its role in higher eukaryotes is less clear. 
We investigated the function of PCNA ubiquitylation using a PCNAK164R mutant 
DT40 chicken B lymphoblastoma cell line, which is hypersensitive to DNA damaging 
agents such as methyl methanesulfonate (MMS), cisplatin or ultraviolet radiation 
(UV) due to the loss of PCNA modifications. In the PCNAK164R mutant we also 
detected cell cycle arrest following UV treatment, a reduced rate of damage bypass 
through translesion DNA synthesis on synthetic UV photoproducts, and an increased 
rate of genomic mutagenesis following MMS treatment. PCNA-ubiquitin fusion 
proteins have been reported to mimic endogenous PCNA ubiquitylation. We found 
that the stable expression of a PCNAK164R-ubiquitin fusion protein fully or partially 
rescued the observed defects of the PCNAK164R mutant. The expression of a 
PCNAK164R-ubiquitinK63R fusion protein, on which the formation of lysine 63-linked 
polyubiquitin chains is not possible, similarly rescued the cell cycle arrest, DNA 
damage sensitivity, reduction of translesion synthesis and increase of MMS-induced 
genomic mutagenesis. Template switching bypass was not affected by the genetic 
elimination of PCNA polyubiquitylation, but it was reduced in the absence of the 
recombination proteins BRCA1 or XRCC3. Our study found no requirement for 
PCNA polyubiquitylation to protect cells from replication-stalling DNA damage. 
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PCNA, proliferating cell nuclear antigen; Ub, ubiquitin; TLS, translesion synthesis; 
TSw, template switching; MMS, methyl methanesulfonate; UV, ultraviolet radiation; 
SNV, single nucleotide variation; HR, homologous recombination 
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1. INTRODUCTION 
The successful bypass of sites of DNA damage during the replication of chromosomal 
DNA is essential for cell survival and the maintenance of genome integrity. PCNA is 
a key protein in DNA replication, DNA repair and cell cycle regulation (Maga and 
Hubscher, 2003; Moldovan et al., 2007). Post-translational modifications 
(ubiquitylation or sumoylation) of PCNA play an important role in regulating its 
function in lesion bypass during DNA replication. The conserved lysine 164 side 
chain can be monoubiquitylated by the RAD6-RAD18 ubiquitin ligase complex in a 
variety of organisms from yeast to higher eukaryotes (Fox et al., 2011; Hoege et al., 
2002; Simpson et al., 2006). Monoubiquitylated PCNA recruits low fidelity Y family 
DNA polymerases (Pol η, Pol κ, Pol ι) to promote TLS (Bienko et al., 2005; 
Kannouche et al., 2004; Plosky et al., 2006). Monoubiquitylated PCNA can also 
undergo further ubiquitylation catalysed by Ubc13-Mms2 and the Rad5 ubiquitin 
ligase in yeast, or UBC13-MMS2 and the Rad5 orthologues HLTF and SHPRH in 
human cells, resulting in the build-up of short lysine 63 (K63)-linked polyubiquitin 
chains (Branzei et al., 2004; Hoege et al., 2002; Unk et al., 2008; Unk et al., 2006). 
This modification is different from the K48-linked polyubiquitin chain that serves as a 
degradation signal. The K63-linked polyubiquitylation of PCNA was genetically tied 
to a Rad18- and Rad5-dependent error-free bypass mechanism in yeast that uses the 
sister chromatid as an alternative template to extend the stalled DNA strand past a 
lesion in the template (Zhang and Lawrence, 2005). Two alternative mechanisms have 
been proposed for such a template switching process. Two-dimensional gel analysis 
of replication intermediates demonstrated a process that operates through a 
recombinational mechanism, forming sister chromatid junctions behind the replication 
fork (Branzei et al., 2008). Indeed, PCNA polyubiquitlylation-dependent template 
switching in yeast is dependent on the key HR protein Rad51, demonstrating a 
functional overlap between template switching and HR (Branzei et al., 2008; Minca 
and Kowalski, 2010). An alternative mechanism for template switching through the 
reversal and regression of stalled replication forks (Atkinson and McGlynn, 2009; 
Higgins et al., 1976) is supported by the structure-specific helicase ability of Rad5 
(Blastyak et al., 2007), though recently the helicase activity of Rad5 was shown to be 
dispensable for template switching (Ball et al., 2014). 
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Lesion bypass through the use of an alternative template has also been demonstrated 
in higher eukaryotes (Izhar et al., 2013; Szuts et al., 2008), and increased UV-induced 
mutagenesis upon overexpressing K63R mutant ubiquitin indirectly implicates PCNA 
polyubiquitylation in the process (Chiu et al., 2006). However, direct evidence for the 
connection between PCNA polyubiquitylation and damage bypass is lacking. SHPRH 
promotes mutagenic bypass on UV lesions, while HLTF also regulates PCNA 
monoubiquitylation (Lin et al., 2011), which likely contributes to its effect in DNA 
damage tolerance.  
We sought to establish a clear genetic assay for the effect of PCNA polyubiquitylation 
in DNA damage tolerance. As it is not clear which enzymes are capable of 
polyubiquitylation in higher eukaryotes (Krijger et al., 2011; Motegi et al., 2008), we 
opted for the use of PCNA-ubiquitin (PCNA-Ub) fusion proteins in which the ligation 
of ubiquitin units can be controlled by altering the target lysines. The N- or C-
terminal linear fusion of one ubiquitin molecule to PCNA has been shown to partially 
substitute for the endogenous ubiquitylation of PCNA in damage tolerance in S. 
cerevisiae (Parker et al., 2007; Pastushok et al., 2010), S. pombe (Ramasubramanyan 
et al., 2010) and cultured human cells (Qin et al., 2013). The fusion proteins in these 
studies allowed the potential formation of polyubiquitin chains on the fused ubiquitin 
moiety. In our study we used combinations of mutations of the target lysines in the 
endogenous PCNA gene and in expressed C-terminal PCNA-Ub fusion proteins to 
genetically allow or inhibit PCNA polyubiquitylation. Our results suggest that PCNA 
polyubiquitylation is not required for DNA damage tolerance or the prevention of 
mutagenesis in chicken DT40 cells. 
 
 
2. MATERIALS AND METHODS 
 
2.1. Transgenic expression constructs  
For the non-fusion PCNA expression constructs, the full length chicken PCNA coding 
sequence was amplified from the cDNA of the wild type DT40 cell line using primers 
CAGCTAGC(NheI)CAGTCGAC(SalI)ATGTTCGAGGCGCGGCTTGTG (primer 
P1) and CAGGATCC(BamHI)TTAAGAGCCTTCTTGCTGGTCTTCAATC, and 
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cloned into the multiple cloning site of pIRES2-EGFP with SalI and BamHI. PCNA-
IRES-EGFP was amplified with primers P1 and 
CAGCGGCCGC(NotI)TTACTTGTACAGCTCGTCCATGC, cloned into the 
pExpress-derived pXpsn2 (Arakawa et al., 2001; Ross et al., 2005) using SalI and 
NotI, cut with SpeI and cloned into NheI-cut pLoxBsr or pLoxPuro (Arakawa et al., 
2001). For the PCNA-Ub fusion expression constructs, the PCNA coding sequence 
was amplified using primers P1 and 
CACAATTG(MfeI)CTCGGCAGTGCCAGAGCCTTCTTGCTGGTCTTCAATCT, 
thereby removing the stop codon and inserting a C-terminal GTAEQL peptide linker 
in analogy with the GTAEIQ linker used in S. cerevisiae (Parker et al., 2007). A 
ubiquitin coding sequence without the C-terminal two glycines was also amplified 
from cDNA using primers 
GTCACAATTG(MfeI)ATGCAGATCTTCGTGAAAACGTTGACTGG and 
GTCAGGATCC(BamHI)CTA(stop)CCTCAGGCGCAGCACCAGATG. The PCNA 
and ubiquitin sequences were assembled in a vector with a purpose-made multiple 
cloning site. The PCNA K164R modification and the ubiquitin K63R modification 
were generated by site directed mutagenesis. The PCNA-Ub fusion sequences were 
subcloned using MluI into modified, non-loxable pLoxBsr/Puro plasmids, which were 
prepared by amplifying the IRES-EGFP sequence from pIRES2-EGFP using primers 
CAGTCGAC(SalI)AGCAATTG(MfeI)TCACGCGT(MluI)CGCCCCTCTCCCTCCC
C and CAGCGGCCGC(NotI)TTACTTGTACAGCTCGTCCATGCC, cloning into 
pXpsn2 using SalI and NotI, excising the transgene with SpeI and cloning into SpeI-
cut pLoxBsr/Puro. 
 
2.2 In vitro ubiquitylation assay 
Human UBA1 was purchased from Sigma Aldrich. The complex of UBC13-MMS2 
was expressed in baculovirus expression system. Plasmids containg the human 
UBC13 and MMS2 cDNA were purchased from Addgene and recloned into a 
modified pFL baculovirus vector (Fitzgerald et al., 2006). The expression of MMS2 
was under control of the p10 promoter, while the expression of UBC13 in frame with 
and N-terminal His6-tag was controlled under the polh promoter of pFL. The complex 
was expressed in Sf9 insect cells and purified via the N-terminal histidine tag of 
UBC13 on a Ni-NTA (GE Healthcare) affinity column, followed by Q-Sepharose Hi-
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Trap 1 mL (GE Healthcare) and Superdex 200 Increase columns pre-equilibrated with 
20 mM Na-HEPES pH 7.5, 100 mM NaCl, 5% glycerol. Human ubiquitin was 
amplified from human cDNA library and cloned into the pETM-11 vector. The 
protein was expressed in the Rosetta II E.coli strain and affinity purified on a 1 mL 
Ni-NTA (GE Healthcare) column, then further purified on Superdex 75 16/60 size 
exclusion chromatography column (GE Healthcare) pre-equilibrated with 20 mM Na-
HEPES pH 7.5, 100 mM NaCl, 5% glycerol. The full length human HLTF cDNA 
(Unk et al., 2008) was cloned into pFL under the polh promoter. The protein was 
expressed in Sf9 insect cells and was affinity purified in one step on amylose resin 
through its maltose binding protein (MBP) tag in buffer containing 40 mM Na-
HEPES pH 7.5, 10% glycerol, 2 mM 2-mercaptoethanol and 100 mM NaCl. PCNA 
constructs were subcloned into the pET-15b vector (Novagen) and expressed in E. 
coli. The N-terminal his-tagged fusion proteins were affinity purified on Ni-NTA 
Superflow resin (QIAGEN), followed by gel filtration on a Superose 12 column (GE 
Healthcare). Ubiquitylation reactions all contained 40 mM Na-HEPES pH 7.5, 8 mM 
MgCl2, 50 mM NaCl, 1 mM ATP, 250 nM ubiquitin and 100 nM PCNA substrate, 
plus 100 nM UBA1, 250 nM UBC13-MMS2 complex and 250 nM HLTF as 
indicated. Reactions were incubated at 30°C for 60 minutes and stopped with the 
addition of SDS sample buffer. 
2.2. Cell culture and colony survival assay 
This study used a wild type DT40 cell line (Molnár et al., 2014), a PCNAK164R/K164R 
line referred to in the text as PCNAK164R (Arakawa et al., 2006), XPA– and XPA– 
PCNAK164R/K164R cells (Szuts et al., 2008). XPA– BRCA1–/– and XPA– XRCC3–/– cell 
lines were generated by disrupting the single-copy XPA gene in the respective 
heterozygous HR mutants, then disrupting the second allele of BRCA1 (Vandenberg 
et al., 2003) and XRCC3 (Yonetani et al., 2005). 
Cells were grown at 37°C under 5% CO2 in RPMI-1640 medium supplemented with 
7% fetal bovine serum, 3% chicken serum, 50 µM 2-mercaptoethanol and 
penicillin/streptomycin.  
MMS, cisplatin and UV sensitivities were measured using colony survival assays; 
treated cells were plated in culture medium containing 1% methylcellulose (Sigma) 
using a tenfold dilution series, and surviving colonies were counted 10 days later. 
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2.3. Shuttle plasmid lesion bypass assay 
600,000 cells were transfected with 0.1 µg pQ-CPDs shuttle plasmid containing two 
synthetic T-T cyclobutyl pyrimidine dimers in a staggered arrangement (Varga et al., 
2012). The transfections were performed using a Nucleofector device (Lonza) as 
described previously (Varga et al., 2012). The transfected cells were cultured at 37°C 
for 24 hours, then the plasmid was extracted using the Hirt protocol and digested with 
10 U DpnI restriction endonuclease in 10 µl at 37°C for 30 minutes to destroy 
unreplicated dam methylated plasmids. The efficiency of plasmid replication was 
quantified from qPCR measurements as the amount of a recovered DpnI-susceptible 
plasmid fragment divided by the amount of a control fragment (Varga et al., 2012). 
The digested DNA was purified and used as template for PCR amplification with Pfu 
Turbo (Agilent) of a 1369 bp section of DpnI resistant replicated pQ-CPDs using 
primers CAGTCGACTTTTGATTTAGAATTGTCCAC and 
CAGCGGCCGCTTTGCAAGCAGCAGATTACG. To determine in bulk the 
proportion of each common sequence outcome of the replication of the CPD lesion 
containing DNA section, allele specific qPCR primers were used on the PCR product. 
The primer pairs used to distinguish double stranded DNA templates after CPD lesion 
bypass were: GATTTAGAATTGTCCACCTCGCC and 
CCTTACTGCATGGATCGAGCT for GC at the site of both lesions, 
GATTTAGAATTGTCCACCTCGCC and TCCCTTACTGCATGGATCGATTT for 
AA insertion by TLS at the downstream lesion or 
TTTTGATTTAGAATTGTCCACCTCTT and CCTTACTGCATGGATCGAGC for 
AA insertion by TLS at the upstream lesion (the allele specific bases are underlined). 
These primers provide 1.000-100.000 fold enrichment over templates with the 
alternative sequence variants. 
 
2.4. Flow cytometry, cell cycle analysis and Western blotting 
DT40 cells were UV-irradiated, labelled with bromodeoxyuridine, fixed and prepared 
for cell cycle analysis exactly as described (Varga et al., 2012), and analysed using a 
FACSCanto II instrument and FACSDiva 6.1 software (BD Biosciences). EGFP 
expression was measured in live cells using the same instrument.  
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For Western blot analysis, whole cell extracts of DT40 cells were fractionated by 
SDS-PAGE and transferred to a PVDF membrane using wet-transfer. After blocking 
in Tris-buffered saline (TBS) containing 5% dry nonfat milk for 1 h, the membrane 
was incubated with anti-PCNA (PC10, Abcam ab29, dilution 1:20000) at 4°C 
overnight. Blots were washed and incubated with anti-mouse (Sigma A9044, dilution 
1:20000) secondary antibody for 1 h, and developed with the ECL system (Clarity 
Western ECL Blotting Substrate, Bio-Rad Laboratories). Chemiluminescent imaging 
was performed with a ChemiDoc MP system and the band intensities were quantified 
using the ImageLab software (Bio-Rad Laboratories). For the analysis of in vitro 
ubiquitylation, blots were blocked in TBS complemented with 5% bovine serum 
albumin, then incubated with anti-ubiquitin primary antibody (Abcam ab7780, 
dilution 1:1000) in TBS with 3% bovine serum albumin for 3.5 hours at room 
temperature. 
 
2.5. Whole genome sequencing and mutation calling 
For the mutagenesis experiment, a single cell starting clone was isolated from each 
cell line and expanded, then four rounds of MMS (Sigma) treatments were performed 
in weekly intervals. One million cells were treated each time for one hour. Following 
the last treatment, single cell clones were isolated and expanded to two million cells 
prior to genomic DNA preparation using the Gentra Puregene Cell Kit (Qiagen). 
Library preparation used the TruSeq DNA Nano Library Preparation Kit (Illumina) or 
the NEBNext Ultra DNA Library Prep Kit for Illumina (New England Biolabs). 
Sequencing was done on Illumina HiSeq 2500 v4 instruments (2x125bp PE). Library 
preparation and DNA sequencing was done at the Research Technology Support 
Facility of Michigan State University, USA, and at Novogene, Beijing, China. The 
reads were aligned to the chicken (Gallus gallus) reference sequence Galgal4.73, 
duplicate reads were removed and the aligned reads were realigned near indels as 
described (Zamborszky et al., 2017). 
 
Independently arising SNVs and short indels were identified using the IsoMut method 
developed for multiple isogenic samples (Pipek et al., 2017). Data from 40 different 
sequenced DT40 clones was used at this step, which included the samples presented 
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in this article. Briefly, after applying a base quality filter of 30, data from all samples 
were compared at each genomic position, and filtered using optimised parameters of 
minimum mutated allele frequency (0.2), minimum coverage of the mutated sample 
(5), and minimum reference allele frequency of all the other samples (0.93), and also 
filtered using a probability-based quality score calculated from the mutated sample 
and one other sample with the lowest reference allele frequency. The quality score 
threshold was set such that no more than five false positive SNVs would be detected 
in pre-treatment starting clones. Raw sequence data has been deposited with the 
European Nucleotide Archive under study accession number ERP019364. 
 
3. RESULTS 
 
3.1. Model for mimicking the monoubiquitylated form of PCNA 
To analyse and separate the phenotype of mono- and K63-linked polyubiquitylated 
PCNA in vivo, we fused wild type or K63R mutant versions of ubiquitin to the 
carboxy terminus of the non-ubiquitylable K164R mutant form of chicken PCNA. 
The two C-terminal glycine residues were removed from ubiquitin in the fusion 
constructs to prevent further modifications (Parker et al., 2007). Alongside these 
PCNAK164R-Ub and PCNAK164R-UbK63R fusion constructs two further expression 
constructs were made that contained the wild type or K164R mutant PCNA as 
positive and negative controls (Fig. 1A). These constructs also express EGFP as part 
of a bicistronic message with an internal ribosome entry site (IRES) to indicate the 
expression level.  
The PCNA fusion constructs were stably transfected into the DT40 PCNAK164R cell 
line in which the endogenous ubiquitylation/sumoylation site of PCNA is eliminated 
(Arakawa et al., 2006), therefore the effect of ubiquitylation is only from the fusion. 
Unlike the wild type ubiquitin fusion, the fused UbK63R cannot be polyubiquitylated 
through lysine 63, allowing us to genetically test the requirement for K63-linked 
polyubiquitylation. The expression levels of the constructs were carefully matched via 
EGFP expression and anti-PCNA Western blots (Fig. 1B, C). The amounts of the 
fusion proteins in these cell lines were approximately similar to the endogenous 
expression level of PCNA, indicating a 2-fold overexpression of PCNA in the 
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transfected lines. We were unable to detect polyubiquitylated forms of either the 
endogenous PCNA or the fusion constructs in cell extracts by Western blot, therefore 
our studies must be considered primarily genetic, correlating phenotypic changes with 
the losses of potential PCNA post-translational modifications. To explore this issue 
further, we set up an in vitro ubiquitylation assay with human E1 (UBA1), E2 
(UBC13-MMS2) and E3 (HLTF) enzymes, which have been shown to ubiquitylate 
PCNA that is monoubiquitylated by RAD6 and RAD18 (Unk et al., 2008). We 
detected a band consistent with the ubiquitylation of PCNAK164R-Ub, which was 
absent when we used the PCNAK164R-UbK63R substrate (Fig. 1D). The formation of 
this modification was dependent on the E1 and E2 enzymes, and slightly enhanced by 
the presence of HLTF. Interestingly, we did not detect longer ubiquitin chains, 
possibly suggesting that the HLTF preparation had low activity. Although it has been 
suggested that PCNA polyubiquitylation takes place through the addition of pre-
assembled polyubiquitin chains (Masuda et al., 2012), we conclude from these results 
that the PCNAK164R-Ub fusion protein can be further ubiquitylated by UBC13-MMS2 
in the absence of RAD18 in a manner dependent on lysine 63 of ubiquitin. This 
suggests that the PCNA-Ub fusion protein is a suitable substrate for K63-linked 
polyubiquitylation, and provides support for the argument that polyubiquitin chains 
cannot form on the PCNAK164R-UbK63R protein. 
 
3.2. The role of PCNA modifications in UV damage tolerance 
PCNA modifications on K164 are required for the unhindered bypass of the two most 
common UV photoproducts (Szuts et al., 2008; Varga et al., 2012). To test whether 
the forced ubiquitylation of PCNA in the cell lines that express PCNA-Ub fusions can 
substitute for these modifications, we first measured cell cycle progression without or 
with UV irradiation (Fig. 2). Untreated populations had similar cell cycle distribution, 
so without DNA damaging treatment, there appear to be no differences between the 
newly generated cell lines (Fig. 2B). After low-dose UV irradiation and 6 h recovery 
there was a marked increase in cells arrested in S phase in all cell lines (Fig. 2C), but 
after 24 h recovery the cell cycle profile of the wild type cells was very similar to that 
of the untreated cells, with a slight increase in the proportion of cells arrested in S 
phase (Fig. 2D). In contrast, there was a marked increase in G2/M phase cells and a 
reduction of G1 and S phase cells in the PCNAK164R cell line. The expression of wild 
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type PCNA rescued this defect, while the expression of the mutated PCNAK164R 
protein did not. There was a clear, though partial rescue of the UV-induced cell cycle 
delay in the cell lines expressing the PCNAK164R-Ub or PCNAK164R-UbK63R fusion 
proteins, in which 38-39% of the cells were in S phase 24 hours after UV exposure, 
with no significant difference between them (Fig. 2D). The proportion of S phase 
cells in the PCNAK164R-UbK63R expressing line was not significantly different from the 
wild type cell line (p=0.09, t-test), but significantly lower than the rescue line that 
expresses wild type PCNA (p=0.0002) and significantly higher than the PCNAK164R 
and PCNAK164R:PCNAK164R negative controls (p<0.0001 and p=0.0010, respectively; 
due to multiple comparisons, the significance limit should be lowered to p=0.01 in 
this set of tests). This indicates that the single C-terminally fused ubiquitin with or 
without further potential K63-linked ubiquitin modifications can equally substitute for 
PCNA modifications on K164. 
To complement the cell cycle analysis, we measured the UV sensitivity of the cell 
lines using colony formation assays. Compared to the wild type, the PCNAK164R and 
PCNAK164R:PCNAK164R negative control cells were hypersensitive to UV, while the 
cell lines that express the PCNAK164R-Ub and PCNAK164R-UbK63R fusion proteins 
showed similar UV sensitivity to the wild type and the PCNAK164R:PCNA rescue cell 
line (Fig. 3A). This suggests that the potential polyubiquitylation in the PCNAK164R-
Ub expressing cell line is not required for cell survival following UV irradiation. 
 
3.3. PCNA monoubiquitylation is required for efficient translesion synthesis over a 
UV lesion 
We next investigated the influence of PCNA modifications on the choice of damage 
bypass mechanism using a shuttle plasmid assay that can measure the ratio of TLS 
and error-free bypass that uses the complementary strand as template (Szuts et al., 
2008; Varga et al., 2012). In order to investigate DNA damage bypass only, we 
eliminated the primary repair system of UV lesions by creating a nucleotide excision 
repair deficient, XPA– knock-out genetic background in each cell line. We 
investigated the replication products of pQ1-CPDs plasmids that contained one T-T 
CPD lesion on each strand in a staggered arrangement, separated by 28 bp, and 
opposed by a mismatched GC dinucleotide (Varga et al., 2012). The overall 
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proportion of replicated plasmids, calculated from the DpnI resistance of short 
plasmid fragments, was in the 2.2-4.9% range across all the samples, with no 
significant differences found by ANOVA (Fig. 2B). Allele-specific primers were used 
in quantitative PCR reactions to measure the relative quantities of the main sequence 
variants at the lesions among replication products. The insertion of AA opposite either 
lesion indicates TLS, while the presence of GC at the site of both lesions in the 
replication product was taken as evidence of error-free bypass by template switching 
(Fig. 4A). The rare mutagenic TLS outcomes such as TA were not measured, which is 
expected to exclude 11-17% of all TLS events from our analysis (Varga et al., 2012). 
In XPA– cells 61% of successful bypass products bore evidence of TLS, whereas in 
XPA– PCNAK164R we observed a modest but significant reduction (p=0.0284, t-test) in 
the proportion of TLS to a mean of 52% (Fig. 4C). These data, obtained with allele-
specific qPCR, are in very good agreement with earlier data derived from the 
sequencing of individual replication products of the same experiment (Varga et al., 
2012). The reduced proportion of TLS confirms a role for PCNA ubiquitylation in the 
process, and the remaining PCNA ubiquitylation independent TLS is likely due to 
TLS polymerase recruitment through REV1 (Hendel et al., 2011; Szuts et al., 2008).  
The expression of the non-ubiquitylable mutant PCNAK164R did not rescue the TLS 
defect (p=0.0166), whereas the transgenic expression of wild type PCNA fully 
restored the use of TLS for CPD bypass. Importantly, the expression of either PCNA-
Ub fusion construct (PCNAK164R-Ub and PCNAK164R-UbK63R) also restored the 
proportion of TLS to near the 60% level (Fig. 4C). Thus the C-terminally fused 
ubiquitin can substitute for the requirement for PCNA ubiquitylation in the regulation 
of TLS. Moreover, the fusion of K63R-mutant ubiquitin provides the same rescue 
effect, even though it does not allow the formation of polyubiquitin chains. We can 
conclude that PCNA monoubiquitylation is the only PCNA modification that is 
required for the bypass of CPD lesions, and potential polyubiquitylation of PCNA 
does not influence the outcome through either TLS or the use of the sister chromatid 
as template. 
 
3.4. The role of PCNA modifications in the bypass of cisplatin- and MMS-induced 
DNA damage 
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UV photoproducts comprise a specific set of well-studied DNA lesions. To assay the 
role of PCNA polyubiquitylation in the bypass of a wider variety of DNA lesions, we 
treated cells with MMS, an alkylating agent (Wyatt and Pittman, 2006), or cisplatin, 
which generates intrastrand and interstrand crosslinks (Eastman, 1986). The 
PCNAK164R cell line and the PCNAK164R-expressing negative control were 
hypersensitive to both MMS and cisplatin, and the expression of wild type PCNA in 
the PCNAK164R background fully restored sensitivity to the wild type level (Fig. 3B, 
C). In case of MMS, the expression of either the PCNAK164R-Ub or the PCNAK164R-
UbK63R fusion proteins also fully rescued the hypersensitivity, thus the monoubiquitin 
modification was sufficient to support a wild type MMS response. The expression of 
PCNAK164R-Ub or PCNAK164R-UbK63R resulted in similar partial rescue of the cisplatin 
sensitivity of the PCNAK164R cell line (see discussion). 
To further test whether the reduced sensitivity upon the expression of PCNA-
ubiquitin fusions is not due to the increase in the overall amounts of PCNA in the cell, 
we created cell lines expressing matched levels of PCNAK164R-Ub or PCNAK164R-
UbK63R in a wild type background. We found that the presence of endogenous and 
transgenic PCNA together (doubling the amount of endogenous PCNA) did not 
change MMS sensitivity (Fig. 3D), demonstrating the specificity of rescuing effect of 
the fusion proteins in the PCNAK164R background. 
 
3.5. Monoubiquitylated PCNA is sufficient to restore the mutation spectrum 
An important consequence of TLS is the potential generation of somatic mutations, in 
contrast with error-free lesion bypass using an alternative template. Interference with 
PCNA ubiquitylation-dependent template switching is therefore expected to increase 
the rate of mutagenesis. Whole genome sequencing allows the detection of all 
genomic mutations that arise during the course of an experiment, and we recently 
employed this strategy to demonstrate a high rate of mutagenesis in response to MMS 
treatment, with the predominance of T>A and C>A changes amongst base 
substitution mutations (Zamborszky et al., 2017). To use MMS-induced mutations as 
a background for measuring the mutagenic impact of PCNA modifications, we 
repeatedly subjected single cell clones to one-hour treatments with 20 ppm (236 µM) 
MMS, followed by the isolation of post-treatment single cell clones. The 
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identification of unique mutations in cell clones isolated from the treated populations 
indicated increased base substitution mutagenesis in the PCNAK164R cell line 
compared to the wild type (Fig. 5A), with an especially noticeable 2.6-fold increase in 
the number of T>A mutations, primarily in the context of further pyrimidine bases 
(Fig. 5A, B). The expression of wild type PCNA nearly rescued this phenotype, 
reducing both the overall number of SNVs and specifically the T>A mutations. This 
reduction in mutagenesis in the presence of wild type PCNA cannot be the 
consequence of PCNA polyubiquitylation-dependent template switching, as the 
expression of the PCNAK164R-UbK63R fusion protein similarly reduced SNV numbers 
and nearly restored the wild type mutation spectrum (Fig. 5A, B). If, based on their 
identical MMS sensitivity we considered results from the wild type and the two 
rescued cell line samples as belonging to the same distribution, the PCNAK164R sample 
would fall outside the 95% confidence interval for both the overall number of SNVs 
and the T>A mutations. The increased mutagenesis in the PCNAK164R cell line may be 
due to mutagenic REV1-dependent TLS, as shown in the case of UV CPD lesions 
(Varga et al., 2012). 
 
3.6. Template switching bypass uses a recombinational mechanism 
The proportion of bypass events with a template switch outcome was unaffected in 
the PCNAK164R:PCNAK164R-UbK63R mutant (Fig. 4C), arguing against an involvement 
of PCNA polyubiquitylation in template switching bypass. To test whether the 
observed use of the sister chromatid as template requires HR factors, we created XPA– 
BRCA–/– and XPA– XRCC3–/– cell lines. BRCA1 is a critical factor of HR, playing 
roles in controlling the resection of broken double stranded DNA ends (Bunting et al., 
2010) and in the recruitment of the essential HR protein RAD51 (Qing et al., 2011; 
Zhang et al., 2009), while XRCC3 is a RAD51 paralogue that is also required for 
RAD51 recruitment (Bishop et al., 1998). When comparing to the XPA– cell line, 
allele-specific qPCR analysis of replicated pQ1-CPDs plasmids revealed a significant 
increase in the proportional use of TLS from 61% to 74% and 72% due to the 
disruption of XRCC3 and BRCA1 respectively, with a corresponding decrease of 
template switching outcomes (Fig. 4C, p=0.006 and p=0.0428, t-test). The 
disappearance of the apparent template switch events suggests that the use of the 
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sister chromatid as a template during lesion bypass is in large part a BRCA1-
dependent, HR-related mechanism. 
 
4. DISCUSSION 
 
In this study we made use of genetic experiments in the chicken DT40 cell line to 
probe the function of PCNA modifications in DNA damage tolerance and lesion 
bypass. The fusion of a single ubiquitin to PCNA rescued the damage sensitivity of a 
non-ubiquitylable PCNA mutant, and also restored the rate of TLS over CPD UV 
photoproducts. The expression of a PCNA-ubiquitin fusion variant that prevented the 
addition of further ubiquitin units showed identical rescuing phenotypes, 
demonstrating a lack of requirement for PCNA polyubiquitylation in UV and MMS-
induced DNA damage tolerance. 
The conserved K164 residue of PCNA is a platform for different modifications: 
mono- and polyubiquitylation, sumoylation. Researchers have been able to 
specifically test the function of PCNA ubiquitylation using PCNA-ubiquitin fusion 
proteins, which partially rescued damage sensitivity in S. cerevisiae Rad18 mutants 
(Parker et al., 2007; Pastushok et al., 2010), or TLS in S. pombe pcn1-K164R mutants 
(Ramasubramanyan et al., 2010). In contrast, we observed a full rescue of UV and 
MMS damage sensitivity and TLS in PCNAK164R mutant vertebrate cells which 
offered the opportunity to specifically test the requirement for PCNA mono- or 
polyubiquitylation. The full rescue suggests that TLS polymerases are able to bind C-
terminal PCNA-Ub fusion proteins. Though siRNA silencing based experiments in 
human cells suggested that Pol η was not required for DNA damage tolerance 
conferred by PCNA-Ub fusions (Qin et al., 2013), we previously observed an 
identical requirement for PCNA ubiquitylation and Pol η in the bypass of CPD UV 
photoproducts (Varga et al., 2012), and in this study the same wild type level of TLS 
was achieved by the monoubiquitylation-equivalent UbK63R fusion, suggesting that at 
CPD lesions the main function of PCNA ubiquitylation is the recruitment of Pol η. 
TLS is not fully dependent on PCNA ubiquitylation (Hendel et al., 2011; Szuts et al., 
2008), which is concordant with the increased rate of mutagenesis we observed in the 
genome of MMS-treated PCNAK164R cells, which is likely due to mutagenic TLS in 
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the absence of PCNA ubiquitylation. The reduction of the rate of mutagenesis and the 
restoration of the wild type mutagenic spectrum by the expression of the PCNAK164R-
UbK63R fusion may then be explained by the recruitment of alternative, less mutagenic 
TLS polymerases. The only contexts in which we did not observe full rescue by 
‘monoubiquitylated’ PCNA were sensitivity to cisplatin, and recovery from UV-
induced cell cycle arrest. Here, the similar partial rescue by wild type or K63R mutant 
ubiquitin suggests that some further PCNA modification may be needed for damage 
tolerance. A candidate for such modification is PCNA SUMOylation, which is not 
possible at residue K164 in the cell lines that express the PCNA-Ub fusion proteins, 
though it may be necessary to regulate HR during the repair or bypass of cisplatin 
lesions (Gali et al., 2012; Pfander et al., 2005). An alternative explanation one must 
consider for the observed imperfect rescue is that the PCNAK164R-Ub fusion may not 
be a perfect mimic for PCNA monoubiquitylated on K164 with regards to cisplatin 
survival, or, if the PCNAK164R-Ub fusion cannot be properly polyubiquitylated, this 
might demonstrate a requirement for polyubiquitylation under these circumstances. 
The main conclusion from our results is the lack of a detectable requirement for 
PCNA polyubiquitylation. We did not physically detect polyubiquitylation of the 
expressed PCNAK164R-Ub fusion protein in vivo. However, regardless of whether this 
can take place, the full rescue of several PCNAK164R phenotypes by both PCNA-Ub 
fusions provides a genetic demonstration that monoubiquitylation was sufficient for 
tolerance to UV and MMS, bypass of CPD UV photoproducts, and the avoidance of 
MMS-induced genomic mutations. 
Post-translational modification of PCNA with two or more ubiquitin units has been 
observed in multiple experimental systems, including the DT40 cells used in this 
study (Tomi et al., 2014), even though HLTF is absent from the chicken genome. 
What may then be the function of PCNA polyubiquitylation? The structure specific 
helicase activity of Rad5 and its orthologues HLTF and SHPRH provided the best 
lead for a function in replication fork reversal, which is a potential mechanism for 
non-mutagenic template switching bypass. However, HLTF and SHPRH have 
damage-specific and rather complex effects on point mutations, mostly due to their 
influence on TLS (Lin et al., 2011), while a template switching role would predict a 
clear anti-mutagenic function. The ZRANB3 protein can bind polyubiquitylated 
PCNA and promote replication fork remodelling and restart (Ciccia et al., 2012), and 
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emerging evidence suggests a distinct role for fork reversal in the protection of stalled 
replication forks (Neelsen and Lopes, 2015; Schlacher et al., 2011). A role for PCNA 
polyubiquitylation in fork reversal and stabilisation would explain the increased rate 
of chromosome breakage due to the loss of SHPRH or HLTF (Motegi et al., 2008; 
Motegi et al., 2006), and could also explain the incomplete rescue of late S/G2 phase 
arrest we observed with the PCNAK164R-UbK63R fusion. 
In conclusion, our dissection of PCNA post-translational modifications in the DT40 
genetic model suggests there is no requirement for PCNA polyubiquitylation in DNA 
damage tolerance and error-free damage bypass. 
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FIGURE LEGENDS 
Figure 1. PCNA fusion constructs and their expression levels 
(A) Schematic representation of PCNA (positive control), PCNAK164R (negative 
control) and PCNAK164R-Ub fusion protein constructs expressed in the DT40 
PCNAK164R cell line. PCNA mutation at K164 prevents in vivo PCNA ubiquitylation, 
ubiquitin mutation at K63 prevents in vivo polyubiquitylation. (B) Histograms of the 
EGFP fluorescence level of each cell line expressing the respective PCNA construct 
as aligned with panel (A), measured by flow cytometry. (C) The levels of unmodified 
and modified PCNA detected by anti-PCNA blot in whole cell DT40 extracts. The 
percentage of total PCNA that is present as ubiquitin fusion, as measured by 
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densitometry, is indicated above the last two lanes. Ponceau S staining of the 
membrane is shown as loading control. WT stands for wild type in all figures. (D) In 
vitro ubiquitylation assay with the indicated purified components, presented using 
Coomassie Brilliant Blue staining (top panel) and anti-Ub Western blot (bottom 
panel). MMS2, UBC13 and ubiquitin have migrated beyond the bottom of the gel. 
The arrow indicates a ubiquitylated form of the PCNAK164R-Ub fusion protein. Size 
markers are in kDa. 
 
Figure 2. Cell cycle analysis 
The DNA content of DT40 cells of the indicated genotypes were analysed using 
propidium iodide staining (horizontal axis), and the rate of DNA replication using 
anti-BrdU-FITC antibody staining (vertical axis). (A) The rationale for assigning cell 
populations to different cell cycle phases, an apoptotic category with sub-G1 DNA 
content, and an arrested S phase category for non-replicating cells with an S phase 
DNA content. (B, C, D) The percentage of cells in each category. Cell cycle phases 
were measured in untreated cells (B) or following 1 J/m2 UV irradiation and 6 h (C) 
or 24 h recovery (D). The mean and S.E.M of five (three for the 6 h time point) 
independent experiments is shown. 
 
Figure 3. UV, MMS and cisplatin sensitivity 
Colony survival assays measuring the sensitivity of the indicated cell lines to UV (A), 
MMS (B, D) and cisplatin (C). The top legend refers to panels (A-C). The mean of 
three independent experiments is shown, error bars indicate S.E.M. 
 
Figure 4. The influence of PCNA modifications and HR proteins on the choice of 
lesion bypass mechanism 
(A) A schematic representation of the possible bypass outcomes on two T-T CPD 
photoproducts arranged on separate strands of a lesion containing plasmid, each 
opposite a GC dinucleotide. GC at the site of both lesions bears evidence of a 
template switch (TSw), while AA opposite either photoproduct indicates TLS. (B) 
Replication efficiency of the pQ-CPDs plasmid in the indicated cell lines, as 
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measured by qPCR (see Materials and Methods). The mean and S.E.M. of three to 
eight independent measurements is shown. (C) The percentage of template switching 
and TLS outcomes in replicated lesion-containing plasmids recovered from the 
indicated cell lines, measured using allele-specific qPCR. The mean and S.E.M. of 
four to six independent measurements is shown. 
 
Figure 5. Number and mutation spectrum of SNVs 
(A) The number of SNVs and base substitution spectrum of mutations detected 
following four rounds of weekly 1 h treatments with 20 ppm MMS of cell lines of 
indicated genotypes. (B) Triplet mutation spectrum of MMS treatment of the 
indicated cell lines. Each mutation class, as indicated at the top of the panel, is 
separated into 16 categories based on the identity of the preceding and following 
nucleotide as shown at the bottom. 
 
 
Highlights (revised)
• PCNA monoubiquitylation is necessary for efficient translesion synthesis 
• PCNA polyubiquitylation is not required for bypass of UV and MMS-induced 
DNA damage
• Monoubiquitylated PCNA fusion is sufficient to restore the mutation spectrum
• Template switching bypass uses a recombinational mechanism
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